US 8,404,244 · Application 11/883,495 · Granted Mar 26, 2013
US 8,404,244
Papillomavirus l2 n-terminal peptides for the induction of broadly cross-neutralizing antibodies
Estimated expiration
May 7, 2029
2y 212d remaining
Earliest effective filing
Feb 1, 2006
+ 20 years
Feb 1, 2026
PTA +1191d
May 7, 2029
No TD
—
Final
May 7, 2029
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.
Calculation details
Base term
- Filing date
- May 13, 2008
- Earliest effective filing
- February 1, 2006
- Issue date
- March 26, 2013
- PTA
- +1191 days
- Base expiry (before PTA)
- February 1, 2026
February 1, 2006 + 20 years = February 1, 2026 + 1191 PTA days = May 7, 2029
- National stage entry of application PCTUS2006003601, filed Feb 1, 2006
- PRO60/649,249 — Provisional — not used for base term
- PRO60/697,655 — Provisional — not used for base term
- PRO60/752,268 — Provisional — not used for base term
- PRO60/649,249 — Provisional — not used for base term
- PRO60/697,655 — Provisional — not used for base term
- PRO60/752,268 — Provisional — not used for base term
Terminal disclaimers
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 11/883,495 · US 8,404,244
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 8,404,244: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One new public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US8404244Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.